Qiagen (QGEN) Expected to Announce Earnings on Wednesday

Qiagen (NYSE:QGEN) is anticipated to release its Q4 2025 results after the market closes on Wednesday, February 4th. Analysts expect Qiagen to post earnings of $0.59 per share and revenue of $528.5340 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:30 AM ET.

Qiagen (NYSE:QGEN) last announced its earnings results on Thursday, November 6th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The company had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. During the same quarter in the prior year, the company earned $0.60 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Trading Up 0.1%

NYSE QGEN opened at $54.26 on Wednesday. The firm has a market capitalization of $11.46 billion, a PE ratio of 28.01, a P/E/G ratio of 2.60 and a beta of 0.66. The stock’s 50 day moving average is $49.19 and its 200 day moving average is $49.56. Qiagen has a twelve month low of $39.61 and a twelve month high of $57.81. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45.

Wall Street Analyst Weigh In

QGEN has been the topic of several recent analyst reports. Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, January 10th. Citigroup cut shares of Qiagen from a “buy” rating to a “neutral” rating and lowered their target price for the company from $57.89 to $52.63 in a research note on Thursday, December 11th. Deutsche Bank Aktiengesellschaft downgraded shares of Qiagen from a “buy” rating to a “hold” rating and raised their price target for the company from $52.00 to $54.00 in a report on Thursday, January 22nd. Barclays reissued an “overweight” rating and set a $57.89 price objective (up from $55.79) on shares of Qiagen in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and an average target price of $53.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Danske Bank A S bought a new position in shares of Qiagen during the 3rd quarter valued at approximately $36,000. Advisory Services Network LLC purchased a new position in Qiagen during the third quarter worth $64,000. Dark Forest Capital Management LP bought a new position in Qiagen during the third quarter valued at $283,000. XTX Topco Ltd bought a new position in Qiagen during the third quarter valued at $749,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of Qiagen by 0.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 218,591 shares of the company’s stock worth $9,737,000 after acquiring an additional 594 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.